Haveri, AnuSmura, TeemuKuivanen, SuviÖsterlund, PamelaHepojoki, JussiIkonen, NiinaPitkäpaasi, MarjaanaBlomqvist, SoileRönkkö, EsaKantele, AnuStrandin, TomasKallio-Kokko, HannimariMannonen, LauraLappalainen, MaijaBroas, MarkkuJiang, MiaoSiira, LottaSalminen, MikaPuumalainen, TaneliSane, JussiMelin, MeritVapalahti, OlliSavolainen-Kopra, Carita2020-04-202020-04-202020-03-19Haveri, A, Smura, T, Kuivanen, S, Österlund, P, Hepojoki, J, Ikonen, N, Pitkäpaasi, M, Blomqvist, S, Rönkkö, E, Kantele, A, Strandin, T, Kallio-Kokko, H, Mannonen, L, Lappalainen, M, Broas, M, Jiang, M, Siira, L, Salminen, M, Puumalainen, T, Sane, J, Melin, M, Vapalahti, O & Savolainen-Kopra, C 2020, 'Serological and molecular findings during SARS-CoV-2 infection : the first case study in Finland, January to February 2020', Eurosurveillance, vol. 25, no. 11, 2000266, pp. 16-21. https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000266ORCID: /0000-0001-5699-214X/work/72777564ORCID: /0000-0003-2270-6824/work/72779125ORCID: /0000-0001-5400-1250/work/72779661http://hdl.handle.net/10138/314196The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.6engcc_byinfo:eu-repo/semantics/openAccessACUTE RESPIRATORY SYNDROMESYNDROME-ASSOCIATED CORONAVIRUSSARS229EBiomedicine11832 Microbiology and virologyGeneral medicine, internal medicine and other clinical medicineArticleopenAccessc1a6ee94-ed41-4050-bc80-7e41dd8b3398000521058800004